Recce Pharmaceuticals — R&D advance (A$11.18m) extends runway
Recce Pharma

Recce Pharmaceuticals (ASX: RCE)

Last close As at 24/06/2024

AUD0.55

−0.03 (−5.22%)

Market capitalisation

AUD112m

More on this equity

Research: Healthcare

Recce Pharmaceuticals — R&D advance (A$11.18m) extends runway

Recce Pharmaceuticals recently received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital for the R&D tax credit rebates that Recce expects to receive for FY23/FY24 and FY25. We believe this non-dilutive source of funding should extend Recce’s operating runway into FY25. Recce is also continuing to advance its intravenous (IV) R327 formulation in its ongoing Phase I/II study in healthy volunteers, having recently started the 20-minute (3,000mg) dosing cohort. We have made minor adjustments to our valuation and we now obtain a risk-adjusted net present value (rNPV) of A$644.4m (or A$3.16/share), versus A$652.6m previously.

Written by

Pooya Hemami

Analyst - Healthcare

Healthcare

Recce Pharmaceuticals

R&D advance (A$11.18m) extends runway

Financing update

Healthcare

26 March 2024

Price

A$0.48

Market cap

A$98m

US$0.65/A$

Net cash (A$m) at 31 December 2023

1.8

Shares in issue

203.7m

Free float

56.4%

Code

RCE

Primary exchange

ASX

Secondary exchanges

Frankfurt: R9Q,
OTC: RECEF

Share price performance

%

1m

3m

12m

Abs

0.0

(14.4)

(19.8)

Rel (local)

(2.1)

(18.0)

(29.1)

52-week high/low

A$0.8

A$0.4

Business description

Recce Pharmaceuticals is an Australian company developing its novel, broad-spectrum synthetic polymer anti-infective drugs for the treatment of several infectious diseases, including sepsis, burn wound infections, urinary tract infections/urosepsis and diabetic foot infections.

Next events

Start Phase II R327 (IV) study in urinary tract infections

H2 CY24

Analyst

Pooya Hemami OD MBA CFA

+1 646 653 7026

Recce Pharmaceuticals is a research client of Edison Investment Research Limited

Recce Pharmaceuticals recently received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital for the R&D tax credit rebates that Recce expects to receive for FY23/FY24 and FY25. We believe this non-dilutive source of funding should extend Recce’s operating runway into FY25. Recce is also continuing to advance its intravenous (IV) R327 formulation in its ongoing Phase I/II study in healthy volunteers, having recently started the 20-minute (3,000mg) dosing cohort. We have made minor adjustments to our valuation and we now obtain a risk-adjusted net present value (rNPV) of A$644.4m (or A$3.16/share), versus A$652.6m previously.

Year

end

Revenue (A$m)

PBT*
(A$m)

EPS*
(A$)

DPS
(A$)

P/E
(x)

Yield
(%)

06/22

3.1

(11.0)

(0.06)

0.0

N/A

N/A

06/23

4.3

(13.1)

(0.08)

0.0

N/A

N/A

06/24e

5.8

(18.1)

(0.09)

0.0

N/A

N/A

06/25e

6.7

(58.4)

(0.29)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Rapid infusion IV R327 study moves to next cohort

Recce’s priority is to advance the IV formulation of R327, particularly for lead indication sepsis (and/or urosepsis) as well as complicated urinary tract infections (UTIs). The ongoing Phase I/II IV R327 study started assessing a 15-minute infusion rate in November and in March 2024, Recce confirmed that the 3,000mg dose administered at varying infusion times between 15 and 60 minutes was shown to be safe. The study’s independent safety committee (ISC) also cleared the study to proceed to the next dosing infusion level of 3,000mg within a 20-minute interval, and we understand that the first subjects of this (20-minute) cohort have now been dosed, with the rest expected to be dosed over the coming weeks. This trial is expected to inform optimal dosing levels and infusion rates for a subsequent Phase II study in UTI patients, which we project will start in H2 CY24.

DFI study receives clearance to expand study sites

Following positive efficacy results reported in January among five patients treated in its Phase I/II study of topical R327 in patients with diabetic foot infections (DFI), the company received approval in February 2024 from the trial’s independent safety committee to expand this programme to additional domestic and global sites. Recce plans to open additional sites over the coming months, which we anticipate will include countries in South-East Asia through its strategic partnership with PT Etana Biotechnologies.

Valuation: Minor adjustments bring rNPV to A$644.4m

We continue to determine an rNPV for Recce, applying a 12.5% discount rate to its four primary development programmes. Our core valuation and modelling assumptions are essentially unchanged. Following minor adjustments (discussed below), we now obtain a new rNPV valuation, inclusive of A$1.8m H124 net cash as of 31 December 2023, of A$644.4m (or A$3.16 per share), versus A$652.6m (or A$3.20 per share) previously.

A$11.18m R&D advance lengthens funding runway

Recce recently announced that it received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital, whereby Endpoints provided the funding to Recce as an advance credit for the R&D tax credit rebates that Recce expects to receive for FY23/FY24 and FY25. For FY23 (the period ending June 2023), Recce had already received A$2.28m from the Australian government as a R&D expenditure rebate in November 2023 (the first of three expected tranches); it expects to receive a second tranche of A$3.04m in Q1 CY24 and the third tranche of A$0.35m in Q2 CY24. The R&D advance credit from Endpoints does not entail or result in any share dilution and accrues interest at 15% per year. It can be repaid as the company receives R&D rebates through the relevant Australian tax authorities.

We remind readers that in late CY23 Recce secured a landmark commitment from the Australian government to provide up to A$55m in future cash rebates to reimburse upcoming R&D expenditure directed towards the company’s proprietary synthetic anti-infective programmes to June 2025. Notably, this binding agreement with the Australian government’s Department of Industry, Science and Resources (AusIndustry) extends the rebate programme that customarily reimburses 43.5% of eligible R&D expenditures incurred within Australia, to cover the anti-infective R&D activities Recce undertakes anywhere in the world. We continue to expect that the bulk of Recce’s upcoming R&D funding will be directed towards its lead synthetic anti-infective candidate, R327, which is designed to work on multiple levels by interrupting bacterial energy production and cell division and affecting cell membrane permeability, to continuously kill bacteria. Recce is advancing R327 as an IV formulation for the treatment of sepsis and for complicated UTIs (cUTIs) and urosepsis, and in topical formulations for burn wound infections and DFIs.

The company reports that it expects this funding advance from Endpoints to not only extend its runway, but to also help accelerate its multiple clinical programmes.

We previously assumed that Recce’s cash on hand would last into Q2 CY24, but with this advance credit, we now believe the company will be funded into Q3 CY24 or FY25 (as detailed in the Financials section below).

Phase I/II IV R327 rapid infusion study advances to next cohort

We continue to view the IV formulation as Recce’s strongest commercial opportunity, specifically the sepsis (and/or urosepsis) and cUTI indications. The company is prioritising development in this area as its continues to advance a Phase I/II study (trial ID ACTRN12623000448640 at anzctr.org.au) assessing the safety, tolerability and pharmacokinetics of R327 IV at faster infusion rates (compared to R327-001, its initial single-dose IV R327 dose escalation trial). Recce expects that faster infusion rates could enable broader access to the drug in primary care and acute patient care settings.

The company reported in September 2023 that it had successfully completed a cohort of both males and females at a 3,000mg dose level at an infusion rate of 30 minutes, which the study’s ISC unanimously deemed safe and well tolerated in October. The ISC then permitted the trial to proceed to the next planned dosing cohort of 3,000mg at a 15-minute infusion rate. In November, Recce reported that the first male and female subjects of this cohort had completed dosing (of 3,000mg) at this faster 15-minute infusion rate as part of the trial. Most recently, in March 2024, Recce confirmed that the 3,000mg dose administered at varying infusion times between 15 and 60 minutes was shown to be safe. The ISC also cleared the study to proceed to the next dosing infusion level of 3,000mg within a 20-minute interval; we understand that the first subjects of this (20-minute) cohort have now been dosed, with the remainder expected to be dosed over the coming weeks. We expect Recce to provide an update thereafter.

Based on the data from the dose-escalation phase in healthy volunteers of the above trial, optimal dosing levels and infusion rates will be decided for the subsequent clinical studies for IV R327 in UTIs and/or urosepsis.

We expect Recce to submit an Investigational New Drug application to the US FDA and then start a multiple-dose global (ie including US sites) Phase II efficacy study in UTIs/urosepsis in H2 CY24. We assume that if the results of the urosepsis study are positive, the pivotal Phase III programme (and overall commercial sepsis programme) would include all forms of sepsis. We anticipate the start of such pivotal sepsis studies (in Europe and the United States) in H2 CY25 and we maintain our estimate for potential approval and commercialisation in sepsis in H2 CY28.

Topical R327 DFI study to expand after positive ISC review

In February 2024 Recce announced that the ISC for its ongoing Phase I/II study assessing topical R327 in skin and soft tissue DFIs unanimously agreed to expand the study based on an interim analysis of the patients that had been treated to date. The ISC at Liverpool Hospital NSW reviewed all the data to date of the study (where R327 was dosed either daily or every other day) and confirmed the study is achieving its primary safety, tolerability and efficacy endpoints (including resolving or curing bacterial DFIs).

As a reminder, Recce first announced in January 2024 that the results to date from this study (discussed in further detail in our prior note) had met all primary endpoints and it was working to expand the study both domestically and internationally. With the ISC now allowing for study expansion, Recce can proceed with adding clinical trial sites both in Australia and internationally, for the treatment of DFIs with topical R327. The company expects to include additional study sites in the coming months.

We anticipate Recce will likely consider study sites in Indonesia and other ASEAN member state countries (which collectively cover 670 million individuals) given the company’s recently announced strategic partnership and MoU in South-East Asia with Indonesian biomedical company Etana. The MoU is designed to facilitate the development, assessment and potential commercialisation of Recce’s broad-spectrum antimicrobial compounds and we note that more than 10% of Indonesia’s population (or c 19.5 million people) have diabetes, resulting in an increased risk for DFIs.

Diabetic foot ulcers are frequent complications of patients who have diabetes mellitus, if the condition is not adequately controlled. Approximately 37 million people have diabetes in the United States. Of them, about 2–4% will obtain foot ulceration each year, of which 50–60% will result in DFIs, the leading cause of foot morbidity in diabetic patients. Diabetes is reported to be the leading cause of non-traumatic lower extremity amputations in the US. Recce believes that topical R327 could potentially be useful in mild DFIs (as more advanced cases require systemic antibiotics), and the recently reported results (January 2024) on five patients provide signs of proof-of-concept and early indications of efficacy (in terms of clearing infection) for topical R327 in this indication.

We continue to estimate that the company could start a Phase III pivotal programme for DFIs in CY25, which we model could lead to launch in CY29.

We note that in addition to assessing topical R327 in DFI, a Phase I/II trial for topical R327 in burn wound infections, sponsored by the West Australian health department and conducted at Fiona Stanley Hospital, remains ongoing. In August 2023 the company announced it had completed stage one of this investigator-led study and will proceed with stage two of the trial, which aims to access a greater population and compare the topical R327 treatment in a head-to-head manner against standard-of-care. Further updates are anticipated during CY24.

Financials: Raise extends runway into late FY24

Recce reported H124 financial results, which are generally consistent with the 4C quarterly cash flow statement (for the quarter ending 31 December 2023, or fiscal Q224). The company reported an H124 operating cash burn rate of A$6.5m, in line with our estimates, and ended the period with a gross cash position of A$4.0m. Recce received a A$2.28m R&D incentive rebate from the Australian government in November 2023 and used part of the proceeds to pay its R&D advance credit liability to Radium Capital, which was recorded at A$2.23m at 31 December (down from A$3.05m at 30 June). Altogether, we calculate H124 net debt at A$1.8m.

We have updated our model to reflect the A$11.18m advance payment received from Endpoints and have reduced our FY24 R&D expense assumptions (to A$15.4m, from A$20.0m previously) as we now expect more of the early costs for the projected multiple-dose Phase II efficacy study in UTIs/urosepsis to be incurred in FY25. We have kept our FY25 and medium-term operating cost assumptions largely unchanged. We have also adjusted our H224 estimates to reflect the additional R&D rebate tranches Recce expects to receive (totalling A$3.4m) from the Australian government in H224 (H1 CY24), although we model that these proceeds will be used to pay the liability to Endpoints. We continue to expect that the company will receive R&D tax credit proceeds (or grants) at 43.5% of prior-year R&D expenditure levels.

We continue to expect R&D expenditure to rise significantly in FY25 (starting H2 CY24), as we project costs for the US Phase II multi-dose UTI/urosepsis study will then start to ramp up, and we anticipate increasing costs for the DFI programme with global trial site engagement. We assume clinical trial activities for each of the four sought indications in our model (sepsis, UTIs, DFIs and burn wounds) will ramp up in FY25. Any delays to the start of such activities would reduce our funding estimates over this period but may push back our potential launch forecasts.

We now anticipate FY24 and FY25 net operating cash burn rates of A$16.9m (down from A$24.7m previously) and A$58.2m (up from A$54.9m previously). The primary driver for the increase in FY25 is the increased assumptions for the cost of debt (given the 15% pa cost of the Endpoints liability).

Given the advance credit from Endpoints, we now estimate Recce’s cash runway lasts into FY25 (Q3 CY24), versus Q2 CY24 previously. We model that the company will raise A$60m in FY25.

Depending on the availability of capital, the company may decide to prioritise certain programmes, which may affect the timing of launches in non-prioritised indications and affect our overall valuation. Our current funding model assumes Recce will advance all four programmes in parallel. However, if it prioritises sepsis (and/or urosepsis) and cUTIs and puts its remaining development programmes on hold until the initial R327 commercial approval, this would reduce its overall funding need as it could subsequently apply post-launch commercial revenue towards resuming R&D and product development activities in the remaining targeted indications. In addition, partnerships and/or non-dilutive forms of funding (such as third-party sponsorship of clinical trials) could also reduce the future funding need, although these are not specifically included in our forecasts.

We view sepsis as the primary driver of the company’s valuation and expect Recce will prioritise the sepsis (and/or urosepsis) and cUTI indications. Assuming the company continues to develop all four planned clinical-stage indications, we now assume Recce would need to raise an additional A$200m (vs A$205m previously) in total net proceeds by FY29 before becoming sustainably cash flow positive. As per the usual Edison methodology, we model these raises as illustrative debt.

We note that the company has an at-the-market (ATM) equity financing facility with Acuity Capital that expires in January 2026, which provides it with up to A$20m of standby equity capital. Recce is not required to use the ATM and may terminate it at any time without cost or penalty.

Valuation

We continue to determine an rNPV for Recce, applying a 12.5% discount rate to its four primary development programmes. Our core valuation and modelling assumptions are essentially unchanged (see our initiation note for details). Given the minor adjustments described above, we now obtain a new rNPV valuation, inclusive of A$1.8m H124 net cash as of 31 December 2023, of A$644.4m (or A$3.16 per share), versus A$652.6m (or A$3.20 per share) previously.

As stated earlier, our model assumes all future financing needs will be raised through illustrative debt, as per usual Edison methodology. If our projected funding need of A$200m is raised through equity issuances at the prevailing market price of c A$0.45, our effective value per share would decrease to A$1.30 (including cash raised via equity).

Exhibit 1: Recce Pharmaceuticals rNPV valuation

Product

Indication

Launch

Sales (A$m) in 2032

NPV (A$m)

Probability of success

rNPV (A$m)

rNPV/basic share (A$)

R327 (IV)

Sepsis

H2 CY28

3,599

4,175

15%

614

3.01

R327 (IV)

Complicated UTI

CY29

387

448

15%

55

0.27

R327 (topical)

Burn wounds

CY28

275

269

20%

42

0.21

R327 (topical)

DFI

CY29

128

125

15%

8

0.04

Corporate costs

(75.6)

(75.6)

(0.37)

Net cash (debt) at 31 December 2023

1.8

1.8

0.01

Total equity value

644.4

3.16

Source: Edison Investment Research

Exhibit 2: Financial summary

A$(000)

2020

2021

2022

2023

2024e

2025e

Year end 30 June

IFRS

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

1,122

1,857

3,085

4,311

5,771

6,692

Cost of Sales

0

0

0

(0)

(0)

(0)

Gross Profit

1,122

1,857

3,085

4,311

5,771

6,692

Sales, General & Administrative

(3,136)

(9,511)

(7,677)

(9,779)

(7,591)

(8,078)

Net Research & Development

(2,071)

(5,657)

(6,285)

(7,330)

(15,385)

(51,154)

EBITDA

 

 

(4,085)

(13,311)

(10,878)

(12,797)

(17,204)

(52,540)

Depreciation & amortisation of intangible assets

0

0

0

0

0

0

Depreciation, amortisation & other

(201)

(296)

(188)

(217)

(380)

(283)

Normalised Operating Profit (ex. amort, SBC, except.)

(4,231)

(8,389)

(10,809)

(12,689)

(17,585)

(52,823)

Operating profit before exceptionals

(4,286)

(13,607)

(11,065)

(13,014)

(17,585)

(52,823)

Exceptionals including asset impairment

0

0

0

54

0

0

Other

0

0

0

0

0

0

Reported Operating Profit

(4,286)

(13,607)

(11,065)

(12,960)

(17,585)

(52,823)

Net Finance income (costs)

(31)

94

79

(117)

(471)

(5,620)

Profit Before Tax (norm)

 

 

(4,317)

(13,513)

(10,986)

(13,131)

(18,056)

(58,443)

Profit Before Tax (FRS 3)

 

 

(4,317)

(13,513)

(10,986)

(13,077)

(18,056)

(58,443)

Tax

0

0

0

0

0

0

Profit After Tax and minority interests (norm)

(4,317)

(13,513)

(10,986)

(13,131)

(18,056)

(58,443)

Profit After Tax and minority interests (FRS 3)

(4,317)

(13,513)

(10,986)

(13,077)

(18,056)

(58,443)

Average Basic Number of Shares Outstanding (m)

127.2

155.4

174.1

174.0

191.0

203.7

EPS - normalised (A$)

 

 

(0.03)

(0.09)

(0.06)

(0.08)

(0.09)

(0.29)

EPS - normalised and fully diluted (A$)

 

(0.03)

(0.09)

(0.06)

(0.08)

(0.09)

(0.29)

EPS - (IFRS) (A$)

 

 

(0.03)

(0.09)

(0.06)

(0.08)

(0.09)

(0.29)

Dividend per share (A$)

0.0

0.0

0.0

0.0

0.0

0.0

BALANCE SHEET

Fixed Assets

 

 

505

501

439

608

463

321

Intangible Assets

0

0

0

0

0

0

Tangible Assets

505

501

439

608

463

321

Investments in long-term financial assets

0

0

0

0

0

0

Current Assets

 

 

2,739

21,181

12,185

1,947

2,206

3,905

Short-term investments

0

0

0

0

0

0

Cash

2,682

20,873

11,582

1,562

1,370

3,070

Other

57

308

603

386

836

836

Current Liabilities

 

 

(885)

(1,078)

(2,447)

(4,850)

(4,648)

(4,648)

Creditors

(885)

(1,078)

(2,447)

(1,802)

(2,414)

(2,414)

Short term borrowings

0

0

0

(3,048)

(2,234)

(2,234)

Long Term Liabilities

 

 

(46)

(100)

(115)

(295)

(8,081)

(68,081)

Long term borrowings

0

0

0

0

(7,790)

(67,790)

Other long term liabilities

(46)

(100)

(115)

(295)

(291)

(291)

Net Assets

 

 

2,313

20,504

10,061

(2,589)

(10,060)

(68,503)

CASH FLOW STATEMENT

 

 

 

 

 

 

 

 

Operating Income

(4,286)

(13,607)

(11,065)

(12,960)

(17,585)

(52,823)

Movements in working capital

253

144

1,532

(152)

751

0

Net interest and financing income (expense)

(31)

94

79

(117)

(471)

(5,620)

Depreciation & other

201

296

188

217

380

283

Taxes and other adjustments

55

5,218

256

325

0

0

Net Cash Flows from Operations

 

(3,807)

(7,856)

(9,010)

(12,687)

(16,925)

(58,160)

Capex and capitalised expenditures

(6)

(76)

(40)

(39)

(128)

(140)

Acquisitions/disposals

0

0

0

0

(34)

0

Interest received & other investing activities

0

0

0

0

0

0

Net Cash flows from Investing activities

 

(6)

(76)

(40)

(39)

(161)

(140)

Net proceeds from share issuances

6,980

26,338

287

102

10,585

0

Net movements in long-term debt

0

0

0

0

6,310

60,000

Dividends

0

0

0

0

0

0

Other financing activities

(888)

(215)

(528)

2,604

0

0

Net Cash flows from financing activities

6,092

26,123

(240)

2,706

16,895

60,000

Effects of FX on Cash & equivalents

0

0

0

0

0

0

Net Increase (Decrease) in Cash & equivalents

2,279

18,191

(9,291)

(10,020)

(192)

1,699

Cash & equivalents at beginning of period

403

2,682

20,873

11,582

1,562

1,370

Cash & equivalents at end of period

2,682

20,873

11,582

1,562

1,370

3,070

Closing net debt/(cash)

 

 

(2,682)

(20,873)

(11,582)

1,487

8,653

22,120

Lease debt

83

127

75

251

199

199

Closing net debt/(cash) inclusive of IFRS 16 lease debt

(2,599)

(20,746)

(11,507)

1,737

8,852

22,318

Free cash flow

(3,813)

(7,932)

(9,051)

(12,726)

(17,086)

(58,301)

Source: Company accounts, Edison Investment Research

General disclaimer and copyright

This report has been commissioned by Recce Pharmaceuticals and prepared and issued by Edison, in consideration of a fee payable by Recce Pharmaceuticals. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

This report has been commissioned by Recce Pharmaceuticals and prepared and issued by Edison, in consideration of a fee payable by Recce Pharmaceuticals. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Recce Pharmaceuticals

View All

Latest from the Healthcare sector

View All Healthcare content

Research: Healthcare

Immix Biopharma — Marching towards US clinical trials for NXC-201

Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer Center as the main clinical site for the company’s US multi-site NEXICART-2 trial assessing NXC-201 in relapsed/refractory (r/r) amyloid light chain amyloidosis (ALA). NXC-201 targets B-cell maturation antigen (BCMA) and is differentiated by its low neurotoxicity and short cytokine release syndrome (CRS) duration to date, supporting Immix’s long-term aspiration to launch the first outpatient CAR-T therapy. The NEXICART-2 study will aim to reproduce the initial results from the Phase Ib/IIa NEXICART-1 study, which reported an overall response rate (ORR) of 100% for the first 10 patients treated. Top-line data from the first 40 patients in the NEXICART-2 trial are expected in 2025, which, if positive, will likely be followed by a biologic license application, a significant milestone for the Immix. The pipeline remains engaged, with IMX-110 in Phase Ib/IIa studies for solid tumors and NXC-201 also targeting multiple myeloma (MM) and, potentially, other autoimmune indications (starting H124).

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free